Merit Medical Systems, Inc. (NASDAQ:MMSI) Receives $92.80 Consensus Target Price from Brokerages

Merit Medical Systems, Inc. (NASDAQ:MMSI) has earned a consensus recommendation of “Moderate Buy” from the eleven ratings firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $92.80.

A number of brokerages have recently commented on MMSI. Piper Sandler reissued an “overweight” rating on shares of Merit Medical Systems in a report on Friday, July 10th. Canaccord Genuity Group cut their target price on shares of Merit Medical Systems from $90.00 to $85.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Wall Street Zen downgraded Merit Medical Systems from a “strong-buy” rating to a “buy” rating in a research report on Sunday, April 5th. Barrington Research cut their price objective on Merit Medical Systems from $109.00 to $107.00 and set an “outperform” rating for the company in a report on Monday, April 20th. Finally, Compass Point set a $107.00 price objective on Merit Medical Systems in a research report on Monday, April 20th.

Insider Buying and Selling

In other Merit Medical Systems news, insider Brian G. Lloyd acquired 2,000 shares of the business’s stock in a transaction dated Thursday, May 7th. The stock was bought at an average price of $62.62 per share, with a total value of $125,240.00. Following the purchase, the insider owned 2,000 shares of the company’s stock, valued at approximately $125,240. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Lynne N. Ward sold 5,000 shares of the company’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $62.61, for a total transaction of $313,050.00. Following the completion of the sale, the director directly owned 7,809 shares of the company’s stock, valued at $488,921.49. This trade represents a 39.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.70% of the stock is owned by company insiders.

Institutional Trading of Merit Medical Systems

Hedge funds have recently added to or reduced their stakes in the business. Los Angeles Capital Management LLC purchased a new position in shares of Merit Medical Systems in the fourth quarter worth about $25,000. Maseco LLP purchased a new stake in Merit Medical Systems during the 4th quarter valued at about $26,000. Torren Management LLC bought a new position in Merit Medical Systems during the 4th quarter worth approximately $38,000. Covestor Ltd increased its stake in Merit Medical Systems by 252.6% in the 4th quarter. Covestor Ltd now owns 469 shares of the medical instruments supplier’s stock worth $41,000 after purchasing an additional 336 shares during the period. Finally, Danske Bank A S purchased a new position in Merit Medical Systems in the 3rd quarter worth approximately $42,000. 99.66% of the stock is owned by institutional investors.

Merit Medical Systems Stock Performance

NASDAQ:MMSI opened at $73.99 on Tuesday. The stock has a market cap of $4.41 billion, a P/E ratio of 32.03, a PEG ratio of 2.30 and a beta of 0.52. The company has a quick ratio of 3.46, a current ratio of 5.08 and a debt-to-equity ratio of 0.45. The business’s 50-day moving average price is $66.96 and its two-hundred day moving average price is $72.63. Merit Medical Systems has a twelve month low of $59.74 and a twelve month high of $94.75.

Merit Medical Systems (NASDAQ:MMSI) last issued its quarterly earnings data on Thursday, April 30th. The medical instruments supplier reported $0.94 EPS for the quarter, topping the consensus estimate of $0.84 by $0.10. The company had revenue of $381.88 million during the quarter, compared to analyst estimates of $377.59 million. Merit Medical Systems had a return on equity of 13.54% and a net margin of 9.03%.Merit Medical Systems’s revenue was up 7.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.86 earnings per share. Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS. As a group, equities analysts predict that Merit Medical Systems will post 3.62 EPS for the current fiscal year.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.